Physician profile
Thomas D Rawson
NPI 1417251190
$5,645.23
in general payments reported to CMS, 2019-2025
22 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $888 · 2023: $1,122 · 2024: $1,793 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,155.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,969.50 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $958.55 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $574.12 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $565.69 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $219.84 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $218.96 | 2023-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $197.87 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $149.52 | 2022-2025 | Ingrezza |
| Novo Nordisk INC | $138.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.72 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $99.21 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $87.40 | 2023-2024 | Quviviq |
| Lundbeck LLC | $77.77 | 2024-2025 | Rexulti |
| Corium, LLC | $52.83 | 2024 | Azstarys |
| Braeburn INC. | $48.56 | 2024-2025 | Brixadi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $42.88 | 2022-2023 | Aplenzin |
| Alkermes, INC. | $40.41 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Hologic Sales and Service, LLC | $24.33 | 2022 | |
| Eisai INC. | $22.89 | 2024 | |
| Almatica Pharma LLC | $18.74 | 2023 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $18.24 | 2021 | |
| Glaxosmithkline, LLC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.